Supernus Pharmaceuticals (SUPN) Raw Materials (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Raw Materials data on file, last reported at $31.5 million in Q1 2026.

• On a quarterly basis, Raw Materials rose 263.26% year-over-year to $31.5 million in Q1 2026; TTM through Mar 2026 was $31.5 million, a 263.26% increase from a year earlier, with the FY2025 full-year figure at $31.8 million, up 186.09% from the prior year.
• Raw Materials for Q1 2026 stood at $31.5 million, down from $31.8 million in the prior quarter.
• Over the last five years, Raw Materials for SUPN reached as high as $57.0 million in Q3 2025 and fell as low as $7.5 million in Q2 2022.
• Historically, Raw Materials has averaged $19.8 million across 5 years, with a median of $16.3 million in 2023.
• Across the five-year window, Raw Materials slumped 73.5% in 2022 and soared 392.51% in 2025, its largest moves.
• Year by year, Raw Materials stood at $24.8 million in 2022, then tumbled by 34.43% to $16.3 million in 2023, then sank by 31.63% to $11.1 million in 2024, then soared by 186.09% to $31.8 million in 2025, then decreased by 1.13% to $31.5 million in 2026.
• Per Business Quant data, the three most recent Raw Materials figures were $31.5 million in Q1 2026, $31.8 million in Q4 2025, and $57.0 million in Q3 2025.